Debiopharm International SA announces results of 2 key oncology programs at 2015 AACR Conference

Debiopharm presents preclinical results for 2 anti-cancer targeted therapies Debio 1143 and Debio 1347

News provided by

Debiopharm Group

Apr 16, 2015, 08:00 ET

LAUSANNE, Switzerland, April 16, 2015 /PRNewswire/ -- Debiopharm International SA (Debiopharm), part of Debiopharm Group™, a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, today announced that preclinical data on the investigational compounds Debio 1143 (SMAC mimetic) and Debio 1347/CH5183284 (FGFR 12,3 inhibitor) will be presented at the 2015 Annual meeting of the American Association for Cancer Research (AACR) taking place in Philadelphia.

"Oncology has and will continue to benefit from combined and targeted therapies. Results from these preclinical studies underscore the potential clinical value of our two anti-cancer targeted therapies," said Dr Nigel McCracken, Vice President, Translational Medicine. "Currently both Debio 1143 and Debio 1347 are in Clinical Development and Debiopharm remains committed to exploring new combinations and new indications to provide improved benefit to patients suffering from cancers."

AACR 2015 Abstract

Compound

Title

Date and Time

N°

Debio 1143

SMAC mimetic and radiotherapy synergize to enhance
antitumor immunity in lung cancer by targeting
immunosuppressive cells

 

Sun, Apr 19,
1:00 - 5:00 pm

#283

Debio 1143 synergizes with taxanes, topoisomerase
and bromodomain inhibitors to inhibit growth of lung
adenocarcinoma

 

Mon, Apr 20,
1:00 - 5:00 pm

#2529

The IAP inhibitor Debio 1143 reverses carboplatin resistance
in ovarian cancer cells by inducing both apoptosis and necroptosis

 

Mon, Apr 20,
1:00 - 5:00 pm

#2700

Debio 1347

Characterization of two novel oncogenic FGFR2 fusions
sensitive to the FGFR-selective inhibitor Debio 1347 in

cholangiocarcinoma

 

Sun, Apr 19,
1:00 - 5:00 pm

#689

Formulation switch and pharmacokinetics/pharmacodynamics of
Debio 1347 (CH5183284), a novel FGFR inhibitor, in a first-in-
human dose escalation trial in solid tumors patients

 

Mon, April 20,
8:00 - 12:00 am

Abstract
CT228

Additional poster regarding Debio 1347 to be presented by Chugai
Pharmaceutical, the originator of the compound: Mechanism of
oncogenic signal activation by the novel fusion kinase FGFR3-
BAIAP2L1

Sun, Apr 19,
1:00 - 5:00 pm

Abstract
#123

About Debiopharm International SA
Debiopharm Group™ is a Swiss-based global biopharmaceutical group of four companies active in drug development, GMP manufacturing of proprietary drugs, diagnostics, and investments. Debiopharm International SA is focused on the development of prescription drugs that target unmet medical needs. The company in-licenses, develops and/or co-develops promising biological and small molecule drug candidates for global registration. The products are commercialized through out-licensing to pharmaceutical partners to give access to the largest number of patients worldwide.

For more information, please visit: www.debiopharm.com

We are on Twitter. Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews

Debiopharm International SA Contact

Additional Media Contacts

Christelle Tur

In London

Communication Coordinator

Maitland

[email protected]

Martin Barrows

Tel: +41 (0)21 321 01 11

[email protected]


Tel: +44 (0)20 7395 0444




In New York

Russo Partners, LLC

Marissa Goberdhan

Account Executive

[email protected]

Tel: +1 212-845-4253

SOURCE Debiopharm Group